Amyloïdosis, sarcoidosis and systemic lupus erythematosus

Amyloïdosis, sarcoidosis and systemic lupus erythematosus

Amel Rezgui^1,&, Imene Ben Hassine¹, Monia Karmani¹, Fatma Ben Fredj¹, Chadia Laouani¹

¹Internal Medicine Department, CHU Sahloul, Tunisia

^&Corresponding author
Amel Rezgui, Internal Medicine Department, CHU Sahloul, Tunisia

Introduction    

Systemic lupus erythematosus (SLE) is characterized by a large clinical polymorphism which explains the diagnostic difficulties encountered in some cases. Amyloidosis is histologically diagnosed by the presence of insoluble protein deposits in tissues. The AA amyloid form is secondary to a chronic inflammatory condition due to systemic diseases. The occurrence of renal and multiple organ amyloidosis is exceptional in the course of systemic lupus erythematosus .We report a case of concomitant diagnosis of SLE and amyloidosis.

Patient and observation     

This is a 57 year old female with hypothyroidism history for 20 years who consulted for fever, arthralgia and erythema nodosum. She presented with a 10 day history of subcutaneous nodules in lower limbs, fever, and arthritis .On physical examination, there was hepatosplenomegaly, and no lymphadenopathy. On the skin examination there was hot nodules on the front and sides of the legs. On ophtalmological examination, there wa keratitis. Biological findings showed an elevated erythrocyte sedimentation rate (123 mm during the first hour), a normocytic normochromic non-regenerative anemia (9 g / dl), a positive polyclonal hyper gamma globulin rate (16 g / L), an elevated C-reactive protein rate (190 mg / L), renal failure (creatinine 200 umol / l, Urea 16 mmol / l, Renal clearance: 28 ml / min), anti-nuclear and anti-native DNA antibodies were positive. There was also significant proteinuria (1g/day). Calcium and phosphate balance over a 3 day periods was normal. Chest X-ray showed Mediastinal enlargement suggestive of mediastinal adenomegaly with calcifications (Figure 1). On chest CT there was mediastinal lymph nodes in Barety space and bilateral hilar lymphadenopathy which were partially calcified. There were changes in the lung parenchyma described as ground glass infiltrates with pleural nodules, pleural and pericardial effusions (Figure 2). Tuberculin intradermal test was negative, mycobacteruim tuberculosis wasn't present in gastric fluid. On functional respiratory tests there was distal obstructive deficit with a normal DLCO. Bronchoscopy showed macroscopically normal bronchi. Bronchial biopsies suggested non specific inflammation lesions. Renal Ultrasound revealed poorly differentiated kidneys with a small left kidney, which didn't allow the renal biopsy. Skin biopsy was performed on healthy skin and showed no lupus band. Renal biopsy was contrindicated by the findings of the renal ultrasound. Biopsy of the salivary glands showed chronic sialadenitis the special Congo Redstain revealed amyloid deposits around the vessels and interlobular ducts (Figure 3) which are birefringent amyloid deposits under polarized light (Figure 4). Accordingly, the retained diagnosis was the association of SLE, sarcoidosis (Lofgren syndrome) and amyloidosis. Our patient has already been treated. There was a complete regression of the erythema nodosum lesions under analgesics and potassium iodide after 4 weeks. There were no indications for corticosteroid therapy because kidneys were already affected, CKD stage (Chronic kidney disease) with small dedifferentiated kidneys and there were no signs of activity of sarcoidosis. The patient was prescribed Colchicine® 1mg per day and Nivaquine® 200mg per day. The patient monitoring included a chest CT, a transthoracic echocardiography (which showed regression of the pericardial effusion), creatininemia and Proteinuria. A rectal biopsy was scheduled.

Discussion     

The association SLE and Sarcoidosis has been described in the literature as a non-fortuitous association [1]. The blocking of the reticuloendothelial purification system by immune complexes excess in SLE can enhance the formation sarcoid granulomas.Hepatitis C treatment with IFN-αcan induce sarcoidosis and SLE [2- 4]. There is common cytokininic channel stimulation between the two conditions. Amyloidosis is defined by the extracellular deposition of protein agglomerates all having common tinctorial affinity, a fibrillary appearance in electron microscopy, and a so-called spatial conformation β-pleated sheet [5, 6]. There are several types of amyloidosis according to the nature of the deposits of amyloid proteins [7]. AA amyloidosis is a complication of chronic inflammation (Rhumatoid arthritis, Ankylosing spondylitis, Crohn's disease, Juvenile idiopathic arthritis) or chronic infections such as tuberculosis. Amyloidosis almost never occurs as a complication of SLE [8,9]. There are a number of reasons which make LES and amyloidosis are mutually exclusive: there is low SAA protein levels during active lupus, whereas the developed amyloidosis secondary to SLE shows primarily elevated SAA protein levels (reactive amyloidosis) [10]. There have been nearly 30 reported cases that associate SLE and amyloidosis since 1956.It is most often an AA amyloidosis type. An AL amyloidosis has been described in some lupus with monoclonal gammopathy. The elapsed time from diagnosis of SLE and amyloidosis varies from 1year to 35 years. The diagnosis was concomitant in our patient.In half of the patients, amyloidosis appears in less than five years' time. The occurrence of amyloidosis mechanisms is not very much known.High levels of SAA proteins were found in cases where they were assayed, which showed strong correlation between elevated SAA and amyloïdogenesis. The diagnosis of amyloidosis was confirmed according to histopathological findings after pulmonary, renal, gastric, cardiac and cutaneous biopsies. The association Sarcoidosis and Amyloidosis has been described in the literature. Five cases where reported in the literature with renal amyloidosis. The diagnosis of sarcoidosis in our case is to be discussed. The clinical features are highly suggestive of Lofgren's Syndrome, staged II on chest X-Ray. There no need to histological evidence as it is not mandatory

Conclusion     

Although concomitant SLE and amyloidosis is an exceptional combination it remains possible. Indeed amyloidosis can complicate any chronic inflammatory condition including SLE. It can be localized or generalized. Treatment is directly based on the management of the exacerbations of SLE

Competing interests     

The authors declare no competing interest.

Authors’ contributions     

All the authors had contributed to this work (medical staff, discussion, therapeutic decision and bibliography). All the authors of the manuscript have read and agreed to its content. the manuscript will be freely available to any scientist wishing to use them for non-commercial purposes

Figures     

Figure 1: chest X-ray showing Mediastinal enlargement

Figure 2: mediastinal lymph nodes in Barety space and bilateral hilar lymphadenopathy on chest CT

Figure 3: congo red stain: amyloid deposits around the vessels and interlobular ducts

Figure 4: irefringent amyloid deposits under polarized light

References     

1. Neville E, Mills RG, Jash DK, Mackinnon DM, Carstairs LS, James DG. Sarcoidosis of the upper respiratory tract and its association with lupus pernio.Thorax. 1976 ;31(6):660-4. PubMed | Google Scholar


2. Kikawada M, Ichinose Y, Kunisawa A, Yanagisawa N, Minemura K, Kasuga I et al. Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia. Respirology. 1998;3(1):41-4. PubMed | Google Scholar


3. Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS. Steroid resistant sarcoidosis: Is antagonism of TNFalpha the answer?. ClinSci. 2007;112(5) :281-9. PubMed | Google Scholar


4. Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Int Med. 2003;253(1):18-30. PubMed | Google Scholar


5. Guillevin Loïc, Meyer Olivier, Hachulla Éric, Sibilia Jean. Traité des Maladies et syndromes systémiques . 6th edition. 2016 Lavoisier SAS. PubMed | Google Scholar


6. Rodney Falk H, Raymond LMD, Comenzo MD, Martha Skinner MD. The Systemic Amyloidoses. N Engl J Med. 1997; 337(13):898-909. PubMed | Google Scholar


7. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJM et al. Amyloid fibril protein nomenclature: 2012 recommendations fromthe Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2012;19(4):167-70. PubMed | Google Scholar


8. Gómez-Puerta JA, Cervera R, Moll C, Solé M, Collado A, Sanmartí R. Proliferative lupus nephritis in a patient withsystemic lupus erythematosus and long standing secondary amyloid nephropathy. Clin Rheumatol. 2009 ;28(1):95-7. PubMed | Google Scholar


9. Monteiro P, Abreu P, Salvador MJ, Malcata A. Secondaryamyloidosis and systemic lupus erythematosus. Acta Reumatol Port. 2009;34(2B):400-4. PubMed | Google Scholar


10. Ridley MG, Maddison PJ, Tribe CR. Amyloidosis and systemic lupus erythematosus. Ann Rheum Dis .1984; 43(4):649-50. PubMed | Google Scholar